Ask AI
SC ICI Considerations

CE

SC ICI Delivery Strategies: Practical Considerations for SC Immunotherapies

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 09, 2026

Expiration: January 08, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Atezolizumab [prescribing information]. South San Francisco, CA: Genentech, Inc; 2026.
  2. Atezolizumab and hyaluronidase-tqjs [prescribing information]. South San Francisco, CA: Genentech, Inc; 2026.
  3. Nivolumab [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2025.
  4. Nivolumab and hyaluronidase-nvhy [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2025.
  5. Pembrolizumab [prescribing information]. Rahway, NJ: Merck Sharp & Dohme LLC; 2026.
  6. Pembrolizumab and berahyaluronidase alfa-pmph [prescribing information]. Rahway, NJ: Merck Sharp & Dohme LLC; 2026.
  7. Hyaluronidase recombinant [prescribing information]. San Diego, CA: Halozyme, Inc; 2024.
  8. Locke KW, Maneval DC, LaBarre MJ. ENHANZE drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv. 2019;26:98-106.
  9. Inoue Y. Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration? Transl Lung Cancer Res. 2024;13:947-951.
  10. Moeller J, Green MD, Ramnath N. Pros and cons of subcutaneous versus intravenous administration of immune checkpoint inhibitors in non-small cell lung cancer. Transl Lung Cancer Res. 2024;13:1444-1449.
  11. Merative Micromedex RED BOOK. Atezolizumab; atezolizumab and hyaluronidase-tqjs; nivolumab; nivolumab and hyaluronidase-nvhy; pembrolizumab; pembrolizumab and berahyaluronidase alfa-pmph. merative.com/documents/micromedex-red-book. Accessed July 7, 2026.
  12. Wolters Kluwer Medi-Span Price Rx. Atezolizumab; atezolizumab and hyaluronidase-tqjs; nivolumab; nivolumab and hyaluronidase-nvhy; pembrolizumab; pembrolizumab and berahyaluronidase alfa-pmph. wolterskluwer.com/en/solutions/medi-span/price-rx. Accessed July 7, 2026.
  13. Nabhan CA, Cortellini A, Ma W, et al. Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study. JAMA Oncol. 2021;7:1856-1861.
  14. Chalker C, Voutsinas JM, Wu QV, et al. Performance status as a predictor of poor response to immune checkpoint inhibitors in recurrent/metastatic head and neck cancer patients. Cancer Med. 2022;11:4104-4111.
  15. Guven DC, Martinez-Cannon BA, Testa GD, et al. Immunotherapy use in older adults with cancer with frailty: a young SIOG review paper. J Geriatr Oncol. 2024;15:101742.
  16. Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35:3807-3814.
  17. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193-3198.
  18. Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785-792.